Hulhoven R, Dumont E, Harvengt C
Med Oncol Tumor Pharmacother. 1984;1(3):201-4. doi: 10.1007/BF02934142.
The plasma kinetics of mitoxantrone (MX), a new cytostatic anthracenedione, were investigated with HPLC in five leukemic patients suffering from acute myeloid leukemia, at the dose of 24 mg m-2 infused over 30 min at constant rate. The decay of the plasma concentrations was best fitted to a three compartment model with average elimination half-lives of respectively 4.1 min (alpha-phase), 19.8 min (beta-phase) and 8.9 h (gamma-phase), a mean distribution volume of 317 l m-2 and an average total body clearance of 0.37 l min-1 m-2. The cumulative urinary recovery of unchanged MX was 7.5% of the administered dose in 4 days, with the highest elimination during the first day. No MX urinary metabolites or conjugates have been detected.
采用高效液相色谱法（HPLC）对5例急性髓性白血病患者进行研究，以恒定速率在30分钟内输注剂量为24mg/m²的新型细胞毒性蒽二酮米托蒽醌（MX），考察其血浆动力学。血浆浓度的衰减最符合三室模型，平均消除半衰期分别为4.1分钟（α相）、19.8分钟（β相）和8.9小时（γ相），平均分布容积为317l/m²，平均全身清除率为0.37l·min⁻¹·m⁻²。4天内未变化的MX累积尿回收率为给药剂量的7.5%，第一天消除率最高。未检测到MX的尿代谢物或共轭物。
